SGN-CD70A

SGN-CD70A is an antibody-drug conjugate (ADC) developed to target the CD70 antigen, which is highly expressed on certain tumor cells. The drug consists of a humanized anti-CD70 monoclonal IgG1 antibody linked via a protease-cleavable linker to a cytotoxic DNA-crosslinking agent known as pyrrolobenzodiazepine (PBD) dimer. Upon binding to CD70 on the surface of tumor cells, the ADC is internalized and trafficked to lysosomes where the PBD dimer is released through proteolytic degradation. The released PBD dimer crosslinks DNA, causing double-strand breaks that lead to apoptosis of cancer cells. SGN-CD70A was primarily investigated for use in relapsed or refractory non-Hodgkin lymphoma (including diffuse large B-cell lymphoma and mantle cell lymphoma), follicular lymphoma Grade 3b, cutaneous T-cell lymphoma, and metastatic renal cell carcinoma[2][4][5]. Despite promising preclinical activity in models overexpressing multidrug-resistant genes[4], clinical development was discontinued due to toxicity concerns such as prolonged thrombocytopenia and insufficient efficacy[2][3].

Other names

anti-CD70 antibody-drug conjugate SGN-CD70Aanti-CD-70 antibody-drug conjugate SGN-CD70Aanti-CD 70 antibody-drug conjugate SGN-CD70A